Clinical advice for immunisation providers regarding the administration of 2014 seasonal influenza vaccines

Clinical advice for immunisation providers regarding the administration of 2014 seasonal influenza vaccines

09 April 2014

This ATAGI statement provides clinical advice on the use of 2014 seasonal influenza vaccines including the vaccines brands available in 2014, recommendations for their use and accessibility through the NIP.

One brand of influenza vaccine, bioCSL Fluvax, is not approved by the TGA for use in children less than five years of age and must not be given to this age group. More detailed ATAGI advice on the use of bioCSL Fluvax is provided in this statement.

Influenza causes illness in people of all ages. It is preventable through vaccination. Annual influenza vaccination is necessary to maintain immunity to influenza.

Based on the dominant influenza virus strains predicted to be in circulation in 2014, the H1N1 pandemic influenza virus strain, which was in the southern hemisphere trivalent seasonal influenza vaccine for the past 4 years, is again incorporated in the 2014 seasonal trivalent influenza vaccine.

The second influenza A strain and the influenza B strain, however, are different from previous years. Strains in the 2014 southern hemisphere trivalent seasonal influenza vaccine are:
  • an A/California/7/2009 (H1N1)-like virus, 15 g haemagglutinin (HA) per 0.5 mL dose
  • an A/Texas/50/2012 (H3N2)-like virus, 15 g HA per 0.5 mL dose
  • a B/Massachusetts/02/2012-like virus, 15 g HA per 0.5 mL dose.

This document provides recommendations for the use, unless contraindicated, of the inactivated seasonal influenza vaccines that are available in Australia in 2014. More information on the use of influenza vaccines can be found in The Australian Immunisation Handbook, 10th edition.

(www.immunise.health.gov.au) and the statement by the Therapeutic Goods Administration (TGA) on 2014 seasonal influenza vaccines (www.tga.gov.au).

To view the rest of the alert, please click here.